More about Hawkeye Bio

NJF Capital presents Hawkeye Bio.

Hawkeye is a clinical stage medical technology company focused on the early detection of cancer which is a growing problem for people not traditionally considered to be at risk, such as non smokers. The company is developing novel screening tests for the deadliest cancers to power new consumer behaviour for easy, routine check-ups.

Founded in 2019 and privately held, the company is based in Los Angeles with operations in Ireland and China. The Hawkeye team includes technologists, medical doctors, and thoracic surgeons with a three-decade track record of success in oncology, over 15 years in liquid biopsy biotech development, and hands-on business and regulatory experience spanning the US, Europe, and Asia.

Hawkeye leverages the collective knowledge of an expert team of immunologists, medical oncologists, physicists, and biotech professionals. They share the vision that radical improvements in the diagnosis of early stage disease are the key to lower cancer mortality, and that these solutions must be affordable and plug-compatible with the standard of care.

Hawkeye Bio in the news